logo-loader
viewAmryt Pharma PLC

Amryt Pharma announces 'positive' results from rare skin disease trial

Amryt Pharma PLC's (NASDAQ:AMYT) (LON:AMYT) Joe Wiley talks to Proactive London's Katie Pilbeam after revealing 'positive results' from the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB).

The results showed which products increased the speed of wound healing in the disease and if approved, this would be the first available treatment for EB.

Wiley explains the challenges of such a trial which involved 223 people, 156 of which were children to research a disease that impacts over 500,000 people worldwide.

Quick facts: Amryt Pharma PLC

Price: 195 GBX

AIM:AMYT
Market: AIM
Market Cap: £317.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE gains despite uncertain UK labour market outlook

The FTSE is in positive territory despite UK unemployment rising to its highest level for two years - up to 4.1% with young people from age 16 to 24 particularly impacted. Online grocer Ocado (LON:OCDO) says its switch to delivering Marks & Spencer food has been successful, after...

1 week, 5 days ago

2 min read